Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators

September 5, 2015

Current Topics in Medicinal Chemistry 2015 August 25 [Epub ahead of print] [Link]

Hamaidia M, Staumont B, Duysinx B, Louis R, Willems L.

Abstract

In the absence of a satisfactory treatment of malignant pleural mesothelioma (MPM), novel therapeutic strategies are urgently needed. Among these, immunotherapy offers a series of advantages such as tumor specificity and good tolerability. Unfortunately, MPM immunotherapy is frequently limited by incomplete cell differentiation or feedback loop regulatory mechanisms. In this review, we describe different components of the innate immune system and discuss strategies to improve MPM immunotherapy by using epigenetic modulators.

Posted in Determining Efficacy, Full Archive, Immune-based Therapies, Treatment, Type of Assessment: